"It is averred that during TVG validation over half of the Exsig Kits reported a Cq number of more than 27. PD's IFU advised users to only use tests where IEC (Internal Extraction Control) Cq result is less than 27. The fact that over half of the apparent false negative results reported Cq numbers of more than 26 is further evidence that the assay was flawed and lacked robustness. This fact is further highlighted when the true negative results are also examined as large numbers of those results also returned an IEC Cq result of greater than 26. That a significant number of invalid results was noted across different sites demonstrates that the assay was flawed and not sufficiently robust for use. As such, it was in breach of the Specification as set out in paragraph 14 above, in that it did not perform to the standards reasonably to be expected of a laboratory based in vitro diagnostic device capable of detecting the SARS-CoV2 virus. Further or alternatively, for the same reasons, the Exsig was not of good quality nor free of material defects ..."
"However, the technical failure rate of the TVG study data indicated a significant problem with the method's robustness. The conclusion of the findings from the seven laboratories are further supported by e-mails from Novacyt (PD) (both internally and to NHS laboratories) illustrating steps to rectify what they admit was an issue due to run failures (namely how the optimiser was dispensed and the revoking of software update v 2.7 fast cycling protocol with 2.10.01). This suggests the exsig COVID-19 Direct was not working as intended and that the IFU protocol and software updates were more to blame than the NHS laboratory staff, who were running other diagnostic tests on a routine basis. However, it is not clear if the potential improvements were implemented by all the NHS laboratories."